Objective To study and analyze the efficacy and safety of edaravone in patients with acute cerebral infarction. Methods 88 patients with acute cerebral infarction who were treated in our hospital from December 2016 to December 2017 were enrolled. The 88 patients were divided into routine treatment group by statistical scientific grouping (44 cases) and the edaravone group (44 cases). Among them, the doctors of our hospital used Danhong injection medicine for the patients in the conventional treatment group, and the doctors treated the edaravone drugs on the basis of the Dandan injection drug treatment for the patients in the edaravone group, and then observed the total effective rate of treatment, NIHSS score, Barthel score, and incidence of adverse reactions were compared between the two groups. Results The total effective rate, NIHSS score, Barthel score, and incidence of adverse reactions were significantly different between the edaravone group and the conventional treatment group. The former [97.7％, (2.52±0.72) points, (69.72 ±14.22) points, 4.5％ ] was significantly better than the latter [72.7％, (3.94 ±1.65) points, (55.13 ±10.72) points, 18.2％], and the data comparison was statistically significant (χ2/t value=10.9210, 5.2322, 5.4346, P＜0.05). Conclusion Edaravone is effective and safe in patients with acute cerebral infarction, and it is worth further promotion and use.%目的 研究与分析依达拉奉在急性期脑梗塞患者中的有效性及安全性.方法 选取在2016年12月-2017年12月时间内来该院进行治疗的患有急性期脑梗塞患者88例,随后采取统计学科学分组法将这88例患者分为常规治疗组(44例)与依达拉奉组(44例).其中该院医师对常规治疗组患者采取丹红注射液药物进行治疗,而医师对依达拉奉组患者采取丹红注射液药物治疗的基础上,联合采取依达拉奉药物进行治疗,随后观察两组患者的治疗总有效率、NIHSS评分、Barthel评分以及不良反应发生率等情况.结果 依达拉奉组与常规治疗组患者的治疗总有效率、NIHSS评分、Barthel评分以及不良反应发生率等数据差异显著,前者[97.7％,(2.52±0.72)分,(69.72±14.22)分,4.5％]显著优于后者[72.7％,(3.94±1.65)分,(55.13±10.72)分,18.2％],数据对比差异有统计学意义(χ2值/t值=10.9210,5.2322,5.4346,P＜0.05).结论 依达拉奉在急性期脑梗塞患者中的有效性以及安全性较高,值得进一步推广与使用.
展开▼
